We encourage companies
that project change
that project change
t
t@CaixaCR
- Next week we are hosting with the EIC a #deeptech startup pitching event with some of the most successful #deeptech… https://t.co/Kev8dkxYrc
- RT @EUeic: Calling all investors! ☎️ Want to meet some of the top #SMEs in #deeptech? 📲 Now is your last chance to register for the #EUei…
- Hoy @Expansión recoge la creación de dos nuevos fondos especializados, Criteria Bio Ventures y Criteria Venture Tec… https://t.co/reGx8Fnvct
N
News & events
Caixa Capital Risc acquires a stake in AlgaEnergy, leader in innovation in the microalgae sector
20.07.2021
• CriteriaCaixa's venture capital management company and the CDTI fund Innvierte Economía Sostenible will have a minority stake in the company.
• AlgaEnergy develops and markets biological agricultural inputs that increase the productivity and quality of crops in a sustainable and profitable way, as well as cosmetic and nutrition products, always with a focus on sustainability and functionality for the user.
• This transaction consolidates the growth strategy of the industrial area of Caixa Capital Risc, which channels its new investments through Criteria Industrial Ventures.
• Caixa Capital Risc manages a volume of more than €230 million in over 120 innovative companies in Spain and Portugal.
Other news See all news »
-
Caixa Capital Risc strengthens its commitment to the cybersecurity business by acquiring a stake in start-up company Build38 and searches for success cases of emerging companies
19.01.2021
• Caixa Capital Risc co-leads, together with the German fund eCapital, an investment of 3 million euros in the cybersecurity startup, whose solution represents ... -
Medlumics raises €14M in a Series E financing co-led by Asabys Partners, VI Partners and CDTI Innvierte, together with existing investors Andera Partners, Caixa Capital Risc and Innogest
09.10.2020
• Medlumics develops a unique real-time, photonically guided radiofrequency (RF) irrigated ablation catheter to improve the treatment of Atrial Fibrillation ... -
Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau
08.10.2020
• Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-th...